2. In Vitro and In Vivo Efficacy Evaluation:
Our proficiency extends to the evaluation of efficacy in various disease areas, including oncology, immunology, cardiovascular, and central nervous system, utilizing cellular, tissue, and animal models for comprehensive efficacy assessments.
3. Early-Stage Lead Compound Screening:
With a focus on accelerating drug development, we offer early ADME and PK studies, along with screening for off-target effects in the early stages, including hERG, safety panels, and kinase profiling.